Skip to main content
. 2024 Feb 6;25(6):e14294. doi: 10.1002/acm2.14294

FIGURE 1.

FIGURE 1

(a) Calculation of SCR for prostate (SCR Prostate), CTV (SCR CTV), and prostate plus SV (SCR SV). (b) Distribution of hydrogel spacer for patients 45 (group 1; SCR Prostate, SCR CTV, and SCR SV of 100%, 90.6%, and 66.9%, respectively) and 13 (group 2; SCR Prostate, SCR CTV, and SCR SV of 67.3%, 66.7%, and 62.8%, respectively).